Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia

References

• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017 Jun;16(2):163–180.
   PubMed Web of Science ®Google Scholar
• Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013 May;21(346):f2539.
   Web of Science ®Google Scholar
• Oakley P, Kisely S, Baxter A, et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: A systematic review and meta-analysis. J Psychiatr Res. 2018;102:245–253.
   PubMed Web of Science ®Google Scholar
• Firth J, Siddiqi N, Koyanagi A, et al. The lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675–712.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the study of diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009 Sep;24(6):412–424.
   PubMed Web of Science ®Google Scholar
• Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011 Feb;17(2):97–107.
   PubMed Web of Science ®Google Scholar
• Manu P, Dima L, Shulman M, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015 Aug;132(2):97–108.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001 Apr;46(3):273–281.
   PubMed Web of Science ®Google Scholar
• Falissard B, Mauri M, Shaw K, et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011 Nov;26(6):291–302.
   PubMed Web of Science ®Google Scholar
• Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999 Nov-Dec;40(6):407–414.
   PubMed Web of Science ®Google Scholar
• Álvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders. CNS Drugs. 2008 ;22(7):547–562. [cited 2008 Jul 01].
   PubMed Web of Science ®Google Scholar
• Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015 Oct 10;6(13):1246–1258.
   PubMed Web of Science ®Google Scholar
• Wang J, Lloyd-Evans B, Giacco D, et al. Social isolation in mental health: a conceptual and methodological review. Soc Psychiatry Psychiatr Epidemiol. 2017 Dec;52(12):1451–1461.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Firth J, Schuch FB, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry. 2017 October;16(3):308–315.
   PubMed Web of Science ®Google Scholar
• Wilmot EG, Edwardson CL, Achana FA, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012;55(11):2895–2905.
   PubMed Web of Science ®Google Scholar
• Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med. 2015;66:297–309.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51–57. [cited 2004 Jan 01].
   PubMed Web of Science ®Google Scholar
• Manu P, Khan S, Radhakrishnan R, et al. Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry. 2014;75(6):e573–7.
   PubMed Web of Science ®Google Scholar
• Hamer M, Batty GD. Association of body mass index and waist-to-hip ratio with brain structure: UK Biobank study. Neurology. 2019;92(6):e594–e600.
   PubMed Web of Science ®Google Scholar
• van Den Broek N, Treur JL, Larsen JK, et al. Causal associations between body mass index and mental health: a Mendelian randomisation study. J Epidemiol Community Health. 2018;72(8):708–710.
   PubMed Web of Science ®Google Scholar
• Nguyen JC, Killcross AS, Jenkins TA. Obesity and cognitive decline: role of inflammation and vascular changes. Front Neurosci. 2014;8:375.
   PubMed Web of Science ®Google Scholar
• Bellack AS. Cognitive rehabilitation for schizophrenia: is it possible? Is it necessary? [Note]. Schizophrenia Bull. 1992;18(1):43–50.
   PubMed Web of Science ®Google Scholar
• Fraguas D, Diaz-Caneja CM, Rodriguez-Quiroga A, et al. Oxidative stress and inflammation in early onset first episode psychosis: a systematic review and meta-analysis [Meta-analysis review research support, Non-U.S. Gov’t]. Int J Neuropsychopharmacol. 2017 Jun 01;20(6):435–444.
   PubMed Web of Science ®Google Scholar
• Steullet P, Cabungcal JH, Monin A, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? [Review]. Schizophr Res. 2016 Sep 01;176(1):41–51.
   PubMed Web of Science ®Google Scholar
• MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9:622.
   PubMed Web of Science ®Google Scholar
• Garriga M, Fernandez-Egea E, Mallorqui A, et al. Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model. J Psychiatr Res. 2019;115:29–35.
   PubMed Web of Science ®Google Scholar
• Munthali RJ, Kagura J, Lombard Z, et al. Early life growth predictors of childhood adiposity trajectories and future risk for obesity: birth to twenty cohort. Child Obes. 2017 Oct;13(5):384–391.
   PubMed Web of Science ®Google Scholar
• Peters M, Godfrey C, McInerney P, et al. Chapter 11: scoping reviews. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute reviewer’s manual. Adelaide: The Joanna Briggs Institute; 2017.
   Google Scholar
• Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation. 2012 Jul 3;126(1):126–132.
   PubMed Web of Science ®Google Scholar
• Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):158–168.
   PubMed Web of Science ®Google Scholar
• Balt SL, Galloway GP, Baggott MJ, et al. Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol Ther. 2011 Jul;90(1):179–183.
   PubMed Web of Science ®Google Scholar
• Benelam B. Satiation, satiety and their effects on eating behaviour. Nutr Bull. 2009;34(2):126–173.
   Google Scholar
• Mayfield K, Siskind D, Winckel K, et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol. 2016 Mar;30(3):227–236.
   PubMed Web of Science ®Google Scholar
• Smith GC, Vickers MH, Cognard E, et al. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res. 2009 Nov;115(1):30–40.
   PubMed Web of Science ®Google Scholar
• Smith GC, Vickers MH, Shepherd PR. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem. 2011 Oct;117(4):241–249.
   PubMedGoogle Scholar
• Shin YK, Martin B, Golden E, et al. Modulation of taste sensitivity by GLP-1 signaling. J Neurochem. 2008 Jul;106(1):455–463.
   PubMed Web of Science ®Google Scholar
• Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007 Dec;27(6):662–666.
   PubMed Web of Science ®Google Scholar
• Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010 Sep;127(3):210–251.
   PubMed Web of Science ®Google Scholar
• Opland DM, Leinninger GM, Myers MG Jr. Modulation of the mesolimbic dopamine system by leptin. Brain Res. 2010 Sep;2(1350):65–70.
   Web of Science ®Google Scholar
• Potvin S, Zhornitsky S, Stip E. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Can J Psychiatry. 2015 Mar;60(3 Suppl 2):S26–34.
   PubMedGoogle Scholar
• Jin H, Meyer JM, Mudaliar S, et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008 Mar;100(1–3):70–85.
   PubMed Web of Science ®Google Scholar
• Firth J, Teasdale SB, Jackson SE, et al. Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?. Schizophr Res. 2019;210:301.
   PubMed Web of Science ®Google Scholar
• Zhang Q, He M, Deng C, et al. Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats. Int J Neuropsychopharmacol. 2014 May;17(5):807–818.
   PubMed Web of Science ®Google Scholar
• van der Zwaal EM, Merkestein M, Lam YK, et al. The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature [Original Article]. Int J Obes (Lond). 2012 Feb;36(2):254–261.
   PubMed Web of Science ®Google Scholar
• Goetz RL, Miller BJ. Meta-analysis of ghrelin alterations in schizophrenia: effects of olanzapine. Schizophr Res. 2018 Dec 7.
   Web of Science ®Google Scholar
• Vogt MC, Brüning JC. CNS insulin signaling in the control of energy homeostasis and glucose metabolism – from embryo to old age. Trends Endocrinol Metab. 2013;24(2):76–84.
   PubMed Web of Science ®Google Scholar
• Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007 Feb;32(2):289–297.
   PubMed Web of Science ®Google Scholar
• Guenette MD, Giacca A, Hahn M, et al. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. Schizophr Res. 2013;146(1):162–169. [cited 2013 May 01].
   PubMed Web of Science ®Google Scholar
• Castellani LN, Wilkin J, Abela AR, et al. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. Psychoneuroendocrinology. 2018;98:127–130.
   PubMed Web of Science ®Google Scholar
• Kowalchuk C, Teo C, Wilson V, et al. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. J Psychiatry Neurosci. 2017 Nov;42(6):424–431.
   PubMed Web of Science ®Google Scholar
• Wang HR, Woo YS, Bahk WM. The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review. Int Clin Psychopharmacol. 2016 Nov;31(6):301–306.
   PubMed Web of Science ®Google Scholar
• Raskind MA, Burke BL, Crites NJ, et al. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology. 2007 Feb;32(2):284–288.
   PubMed Web of Science ®Google Scholar
• Terron MP, Delgado-Adamez J, Pariente JA, et al. Melatonin reduces body weight gain and increases nocturnal activity in male Wistar rats. Physiol Behav. 2013 Jun;13(118):8–13.
   Web of Science ®Google Scholar
• van Galen KA, Ter Horst KW, Booij J, et al. The role of central dopamine and serotonin in human obesity: lessons learned from molecular neuroimaging studies. Metabolism. 2018;85:325–339.
   PubMed Web of Science ®Google Scholar
• Singh R, Bansal Y, Medhi B, et al. Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol. 2019 Feb 5;844:231–240.
   PubMed Web of Science ®Google Scholar
• Nielsen MO, Rostrup E, Wulff S, et al. Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment. JAMA Psychiatry. 2016 Feb;73(2):121–128.
   PubMed Web of Science ®Google Scholar
• Blundell JE, Halford JCG. Serotonin and appetite regulation. CNS Drugs. 1998 June 01;9(6):473–495.
   Web of Science ®Google Scholar
• Lord CC, Wyler SC, Wan R, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017 Sep 1;127(9):3402–3406.
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010 Nov;123(2–3):225–233.
   PubMed Web of Science ®Google Scholar
• Rasmussen H, Ebdrup BH, Oranje B, et al. Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients. Int J Neuropsychopharmacol. 2014 Nov;17(11):1729–1736.
   PubMed Web of Science ®Google Scholar
• Kim SF, Huang AS, Snowman AM, et al. From the Cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456–3459.
   PubMed Web of Science ®Google Scholar
• He M, Zhang Q, Deng C, et al. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology. 2014;42:153–164.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Robinson DG, Lencz T, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016 Nov;42(6):1418–1437.
   PubMed Web of Science ®Google Scholar
• Zhang JP, Malhotra AK. Recent progress in pharmacogenomics of antipsychotic drug response [journal article]. Curr Psychiatry Rep. 2018 Mar 27;20(4):24.
   PubMed Web of Science ®Google Scholar
• Suetani RJ, Siskind D, Reichhold H, et al. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Psychopharmacology (Berl). 2017 Oct;234(20):2989–3008.
   PubMed Web of Science ®Google Scholar
• Sainz J, Prieto C, Crespo-Facorro B. Sex differences in gene expression related to antipsychotic induced weight gain. PLoS One. 2019;14(4):e0215477.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Stensland M, Zhao Z, et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005 [cited 2005 Jan 13];5(1):3.
   PubMed Web of Science ®Google Scholar
• Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009 [cited 2009 Jun 01];111(1):9–16.
   PubMed Web of Science ®Google Scholar
• Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res. 2003 Jul 1;62(1–2):77–88.
   PubMed Web of Science ®Google Scholar
• Kanji S, Fonseka TM, Marshe VS, et al. The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. Eur Arch Psychiatry Clin Neurosci. 2018 Feb;268(1):3–15.
   PubMed Web of Science ®Google Scholar
• Davey KJ, O’Mahony SM, Schellekens H, et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl). 2012 May;221(1):155–169.
   PubMed Web of Science ®Google Scholar
• Bahra SM, Weidemann BJ, Castro AN, et al. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine. 2015 Nov;2(11):1725–1734.
   PubMed Web of Science ®Google Scholar
• Davey KJ, Cotter PD, O’Sullivan O, et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry. 2013 Oct;1(3):e309.
   Web of Science ®Google Scholar
• Bahr SM, Tyler BC, Wooldridge N, et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015 Oct;6(5):e652.
   Web of Science ®Google Scholar
• Hallal PC, Andersen LB, Bull FC, et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380(9838):247–257. [cited 2012 Jul 21].
   PubMed Web of Science ®Google Scholar
• Andersen E, Holmen TL, Egeland J, et al. Physical activity pattern and cardiorespiratory fitness in individuals with schizophrenia compared with a population-based sample. Schizophr Res. 2018 [cited 2018 Nov 01];201:98–104.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Firth J, Berry A, et al. How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. Schizophr Res. 2016 Oct;176(2–3):431–440.
   PubMed Web of Science ®Google Scholar
• Teasdale SB, Ward PB, Samaras K, et al. Dietary intake of people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry. 2019;1–9.
   Web of Science ®Google Scholar
• Firth J, Stubbs B, Teasdale SB, et al. Diet as a hot topic in psychiatry: a population‐scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry. 2018;17(3):365–367.
   PubMed Web of Science ®Google Scholar
• Firth J, Cotter J, Elliott R, et al. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015 May;45(7):1343–1361.
   PubMed Web of Science ®Google Scholar
• Pearsall R, Smith DJ, Pelosi A, et al. Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis. BMC Psychiatry. 2014 Apr;21(14):117.
   Web of Science ®Google Scholar
• Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019 Feb;18(1):53–66.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018;54:124–144.
   PubMed Web of Science ®Google Scholar
• Holt RIG, Gossage-Worrall R, Hind D, et al. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. Br J Psychiatry. 2019 Feb;214(2):63–73.
   PubMed Web of Science ®Google Scholar
• Speyer H, Christian Brix Norgaard H, Birk M, et al. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry. 2016 Jun;15(2):155–165.
   PubMed Web of Science ®Google Scholar
• Teasdale SB, Ward PB, Rosenbaum S, et al. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry. 2017 Feb;210(2):110–118.
   PubMed Web of Science ®Google Scholar
• Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1):159–168. [cited 2012 Sept 01].
   PubMed Web of Science ®Google Scholar
• Firth J, Rosenbaum S, Stubbs B, et al. Motivating factors and barriers towards exercise in severe mental illness: a systematic review and meta-analysis. Psychol Med. 2016;46(14):2869–2881.
   PubMed Web of Science ®Google Scholar
• Curtis J, Watkins A, Rosenbaum S, et al. Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. Early Interv Psychiatry. 2016 Jun;10(3):267–76.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Hasnain M, Vieweg WV. Weight considerations in psychotropic drug prescribing and switching. Postgrad Med. 2013 Sep;125(5):117–129.
   PubMed Web of Science ®Google Scholar
• Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635–2647.
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003 Apr;166(4):391–399.
   PubMed Web of Science ®Google Scholar
• TS S, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011 Sep;168(9):947–956.
   PubMed Web of Science ®Google Scholar
• Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002 Jan;24(1):21–37.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008 Apr;33(5):985–994.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bobo WV, Watts K, et al. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol. 2012 Sep;26(9):1201–1210.
   PubMed Web of Science ®Google Scholar
• Moller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101–1111.
   PubMed Web of Science ®Google Scholar
• Lin CC, Bai YM, Wang YC, et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009 Dec;29(6):529–536.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013 Feb;74(2):170–179.
   PubMed Web of Science ®Google Scholar
• Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr. 2014 Aug;19(4):330–339.
   PubMed Web of Science ®Google Scholar
• Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin. 2002;18(4):201–208. [cited 2002 Jan 01].
   PubMed Web of Science ®Google Scholar
• Weber M, Gutierrez AM, Mohammadi M. The risks and benefits of switching antipsychotics: a case study approach. Perspect Psychiatr Care. 2009 Jan;45(1):54–61.
   PubMed Web of Science ®Google Scholar
• Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol. 2009 Aug;19(8):562–570.
   PubMed Web of Science ®Google Scholar
• Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041–1050. [cited 2009 Jul].
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mu F, Ayyagari R, et al. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306. [cited 2018 Sept 24].
   PubMed Web of Science ®Google Scholar
• Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47–53.
   PubMedGoogle Scholar
• Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer [Review Article]. Nat Rev Endocrinol. 2014 Jan 07;10:143. online.
   PubMed Web of Science ®Google Scholar
• Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):27–31.
   PubMed Web of Science ®Google Scholar
• Siskind DJ, Leung J, Russell AW, et al. Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One. 2016;11(6):e0156208.
   PubMed Web of Science ®Google Scholar
• Praharaj SK, Jana AK, Goyal N, et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011 Mar;71(3):377–382.
   PubMed Web of Science ®Google Scholar
• Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacol. 2010 Jun;35(7):1520–1530.
   PubMed Web of Science ®Google Scholar
• Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019 Feb;21(2):293–302.
   PubMed Web of Science ®Google Scholar
• Siskind DJ, Russell AW, Gamble C, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes Obes Metab. 2018 Apr;20(4):1050–1055.
   PubMed Web of Science ®Google Scholar
• Semaglutide: DS. First Global Approval [journal article]. Drugs. 2018 Feb;78(2):275–284.
   PubMed Web of Science ®Google Scholar
• Rege S. Antipsychotic induced weight gain in schizophrenia: mechanismsand management. Aust N Z J Psychiatry. 2008 May;42(5):369–381.
   PubMed Web of Science ®Google Scholar
• Goh KK, Chen CH, Lu ML. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. Int J Psychiatry Clin Pract. 2019 Mar;23(1):14–32.
   PubMed Web of Science ®Google Scholar
• Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology. 2011 Jan 11;76(2):131–137.
   PubMed Web of Science ®Google Scholar
• Hocking S, Dear A, Cowley MA. Current and emerging pharmacotherapies for obesity in Australia. Obes Res Clin Pract. 2017 Sep - Oct;11(5):501–521.
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether, B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077.
   PubMed Web of Science ®Google Scholar
• Nguyen C, Suzuki A, Bera K. Use of Lorcaserin, A 5HT2C Agonist, in the management of olanzapine induced weight gain [Case Report]. J Metab Syndr. 2015;4:4.
   Google Scholar
• ClinicalTrials.gov. Identifier: NCT02796144: mEtformin and Lorcaserin for WeighT Loss in Schizophrenia (MELT). Bethesda, Maryland: U.S. National Library of Medicine; 2016 [cited 2019 Jul 07]. Available from: https://clinicaltrials.gov/ct2/show/NCT02796144?term=lorcaserin&cond=Schizophrenia&rank=1
   Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes care. 2004;27(1):155–161.
   Google Scholar
• Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 May;69(5):706–711.
   PubMed Web of Science ®Google Scholar
• Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag. 2007;3(6):817–821.
   PubMedGoogle Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605. [cited 2010 Aug 21].
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935–943.
   PubMed Web of Science ®Google Scholar
• Tek C. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. Patient Prefer Adherence. 2016;10:751–759.
   PubMed Web of Science ®Google Scholar
• Lian J, Huang XF, Pai N, et al. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways. Psychoneuroendocrinology. 2014;48:77–86.
   PubMed Web of Science ®Google Scholar
• Lian J, Huang XF, Pai N, et al. Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications. Pharmacol Res. 2016;106:51–63.
   PubMed Web of Science ®Google Scholar
• Barak N, Beck Y, Albeck JH. Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol. 2016 Mar;30(3):237–241.
   PubMed Web of Science ®Google Scholar
• Kao AC, Spitzer S, Anthony DC, et al. Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. Transl Psychiatry. 2018 Mar 15;8(1):66.
   PubMed Web of Science ®Google Scholar
• Brown CD, Higgins M, Donato KA, et al. Body Mass Index and the Prevalence of Hypertension and Dyslipidemia. Obes Res. 2000;8(9):605–619.
   PubMedGoogle Scholar
• Ojala K, Repo-Tiihonen E, Tiihonen J, et al. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol. 2008;22(1):33–38.
   PubMed Web of Science ®Google Scholar
• Gugger JJ. Antipsychotic Pharmacotherapy and Orthostatic Hypotension. CNS Drugs. 2011 August 01;25(8):659–671.
   PubMed Web of Science ®Google Scholar
• Citrome L. The ABC’s of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211–1220.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Guidelines for the management of physical health conditions in adults with severe mental disorders. Geneva: WHO; 2018.
   Google Scholar